Japan’s Taiho Pharmaceutical to acquire Swiss Biotech Araris for $1.14 billion
Swiss oncology biotech firm Araris Biotech AG has entered into an acquisition agreement with Taiho Pharmaceutical Co., Ltd, marking a significant milestone for the advanced therapies industry, 4BIO Capital announced Monday. The Japanese company will pay $400 million upfront, with additional milestone…